We narrowed to 102 results for: yfp

#55641-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 25, 2021

Academic Institutions and Nonprofits only

#27056-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA. EF1a-driven, cre-dependent EYFP expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#55641-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 27, 2023

Academic Institutions and Nonprofits only

#100050-AAV9

Ready-to-use AAV9 particles produced from pAAV.CaMKIIa.ChETA(E123T/H134R)-eYFP.WPRE.hGH (#100050). In addition to the viral particles, you will also receive purified pAAV.CaMKIIa.ChETA(E123T/H134R)-eYFP.WPRE.hGH plasmid DNA. CaMKIIa-driven, ChETA(E123T/H134R)-eYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 3, 2018

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#100049-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynap.ChETA(E123T/H134R)-eYFP.WPRE.hGH (#100049). In addition to the viral particles, you will also receive purified pAAV.hSynap.ChETA(E123T/H134R)-eYFP.WPRE.hGH plasmid DNA. Synapsin-driven ChETA(E123T/H134R)-EYFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 21, 2018

Academic Institutions and Nonprofits only

#135633-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#137151-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-NpHR3.3-EYFP (#137151). In addition to the viral particles, you will also receive purified pAAV-nEF-NpHR3.3-EYFP plasmid DNA. nEF-driven expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#135633-AAV5

Ready-to-use AAV5 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Oct. 8, 2020

Academic Institutions and Nonprofits only

#27056-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA. EF1a-driven, Cre-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 10, 2020

Academic Institutions and Nonprofits only

#55641-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Oct. 21, 2024

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#135633-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#26973-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 3, 2018

Academic Institutions and Nonprofits only

#26973-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 30, 2018

Academic Institutions and Nonprofits only

#26973-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 27, 2024

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26969-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26969-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

May 9, 2018

Academic Institutions and Nonprofits only

#26969-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only